| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 9e-07 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-06 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.31 | 2e-05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.0002 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.0002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.19 | 0.0006 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0008 |